Effect of palonosetron in preventing chemotherapy-induced vomiting
10.3969/j.issn.1000-8179.20141171
- VernacularTitle:盐酸帕洛诺司琼注射液预防化疗引起恶心呕吐的临床疗效观察
- Author:
Zhongsheng TONG
;
Shufen LI
;
Rongsheng ZHENG
;
Zhiyong HE
;
Lili ZHANG
;
Xuenong OUYANG
;
Jinfei CHEN
;
Hao YU
;
Yehui SHI
;
Xu WANG
;
Xiaoxin LI
;
Yishan ZHANG
- Publication Type:Journal Article
- Keywords:
palonosetron;
granisetron;
chemotherapy;
vomiting
- From:
Chinese Journal of Clinical Oncology
2014;(20):1323-1327
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of palonosetron in preventing chemotherapy-induced vomiting. Meth-ods:A multi-center, randomized, double-blind, and self-cross-over positively controlled clinical trial design was used. All patients were randomized into two groups, as follows:Regiment A (61 cases) and Regiment B (64 cases). Regimen A with palonosetron hydrochlo-ride injection (test agent) was used in the treatment cycle A, whereas granisetron hydrochloride injection (control drug) was used in the cycle B. Treatments were randomly administered on the patients of the two groups. Regimen B was on the contrary, the control drug was used in the cycle A, and the test agent was used in the treatment cycle B. All patients treated with the test agent were classified as the test group, whereas those treated with the control drug were classified as the control group. Complete control rate and adverse reac-tion of acute and delayed vomiting in the two groups during the two cycles of chemotherapy regimen were compared. Results: In Group One, the complete control rate of delayed vomiting was significantly higher in the palonosetron administration cycles than in the granisetron cycles (76.92%vs. 55.38%, P=0.0110). In the same group, the frequency of vomiting was significantly less in palonosetron cycles than in the granisetron cycles during day 1 to day 5 (1.32±3.42 vs. 1.94±3.03, P=0.0096). The incidences of adverse effects were low in both groups. No grades 3 and 4 adverse effects were observed. Conclusion: Palonosetron showed efficacy in preventing the acute and delayed chemotherapy-induced vomiting. The drug is superior to granisetron, specifically in delaying vomiting in Group One. Palonosetron hydrochloride showed slight adverse effects. Hence, this drug can be used in clinic.
